Patents by Inventor Peter G. Schultz

Peter G. Schultz has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • INSULIN IMMUNOGLOBULIN FUSION PROTEINS
    Publication number: 20190023794
    Abstract: Disclosed herein are immunoglobulin fusion proteins comprising an insulin therapeutic peptide and an immunoglobulin region that targets the insulin therapeutic peptide to the liver of an individual in need thereof. Further disclosed herein are compositions comprising the immunoglobulin fusion proteins and methods for using the immunoglobulin fusion proteins for the treatment or prevention of a disease or condition in a subject, for example, diabetes and diabetes related conditions.
    Type: Application
    Filed: September 2, 2016
    Publication date: January 24, 2019
    Inventors: Feng WANG, Matthew S. TREMBLAY, Travis YOUNG, Nicole ALVAREZ, Yan LIU, Juanjuan DU, Peter G. SCHULTZ
  • MODIFIED THERAPEUTIC AGENTS AND COMPOSITIONS THEREOF
    Publication number: 20190000928
    Abstract: Methods and compositions are provided for extending the half-life of a therapeutic agent. A modified therapeutic agent (mTA) comprises a therapeutic agent, a staple, and a half-life extending molecule. The mTAs disclosed herein may be used to treat a disease or a condition in a subject in need thereof.
    Type: Application
    Filed: June 16, 2016
    Publication date: January 3, 2019
    Inventors: Weijun SHEN, Pengyu YANG, Peter G. SCHULTZ
  • COMPOSITION AND METHODS FOR INHIBITING MAMMALIAN STERILE 20-LIKE KINASE 1
    Publication number: 20180362497
    Abstract: Disclosed herein are compounds, compositions, and methods of their use for the treatment of diabetes.
    Type: Application
    Filed: June 24, 2016
    Publication date: December 20, 2018
    Inventors: Hank Michael James PETRASSI, Murali Mohan Reddy PERAM SURAKATTULA, Kathrin MAEDLER, Amin ARDESTANI, Jason T. ROLAND, Tyler D. BAGULEY, Matthew S. TREMBLAY, Weijun SHEN, Peter G. SCHULTZ, Arnab K. CHATTERJEE
  • MODIFIED THERAPEUTIC AGENTS, STAPLED PEPTIDE LIPID CONJUGATES, AND COMPOSITIONS THEREOF
    Publication number: 20180344812
    Abstract: Methods and compositions are provided for extending the half-life of a therapeutic agent. A modified therapeutic agent (mTA) comprises a therapeutic agent, a staple, and a half-life extending molecule. The mTAs disclosed herein may be used to treat a disease or a condition in a subject in need thereof.
    Type: Application
    Filed: June 5, 2018
    Publication date: December 6, 2018
    Inventors: Weijun Shen, Pengyu Yang, Huafei Zou, Peter G. Schultz
  • METHODS FOR TREATING VIRAL INFECTIONS
    Publication number: 20180271873
    Abstract: Described herein are methods for treating a viral infection comprising administering to an individual in need thereof a therapeutically effective amount of a compound of Formula I: Formula (I).
    Type: Application
    Filed: March 31, 2016
    Publication date: September 27, 2018
    Inventors: Jason T. ROLAND, Arnab K. CHATTERJEE, Peter G. SCHULTZ, Shoutian ZHU, Timothy WRIGHT, Tyler BAGULEY
  • Modified therapeutic agents, stapled peptide lipid conjugates, and compositions thereof
    Patent number: 10039809
    Abstract: Methods and compositions are provided for extending the half-life of a therapeutic agent. A modified therapeutic agent (mTA) comprises a therapeutic agent, a staple, and a half-life extending molecule. The mTAs disclosed herein may be used to treat a disease or a condition in a subject in need thereof.
    Type: Grant
    Filed: December 17, 2014
    Date of Patent: August 7, 2018
    Assignees: THE CALIFORNIA INSTITUTE FOR BIOMEDICAL RESEARCH, THE SCRIPPS RESEARCH INSTITUTE
    Inventors: Weijun Shen, Pengyu Yang, Huafei Zou, Peter G. Schultz
  • MODIFIED THERAPEUTIC AGENTS AND COMPOSITIONS THEREOF
    Publication number: 20180207276
    Abstract: Methods and compositions are provided for extending the half-life of a therapeutic agent. One half-life extending moieties may be attached to a therapeutic agent, thereby extending the half life of the therapeutic agent. The modified therapeutic agents comprising a half-life extending moieties attached to a therapeutic agent may be used to treat a disease or condition in a subject in need thereof.
    Type: Application
    Filed: March 17, 2016
    Publication date: July 26, 2018
    Inventors: Weijun SHEN, Avinash MUPPIDI, Peter G. SCHULTZ
  • Modified therapeutic agents, stapled peptide lipid conjugates, and compositions thereof
    Patent number: 10010589
    Abstract: Methods and compositions are provided for extending the half-life of a therapeutic agent. A modified therapeutic agent (mTA) comprises a therapeutic agent, a staple, and a half-life extending molecule. The mTAs disclosed herein may be used to treat a disease or a condition in a subject in need thereof.
    Type: Grant
    Filed: December 17, 2014
    Date of Patent: July 3, 2018
    Assignees: THE CALIFORNIA INSTITUTE FOR BIOMEDICAL RESEARCH, THE SCRIPPS RESEARCH INSTITUTE
    Inventors: Weijun Shen, Pengyu Yang, Huafei Zou, Peter G. Schultz
  • Small molecule inhibitors of fibrosis
    Patent number: 9981956
    Abstract: Described herein are compounds and compositions for the treatment of a fibrotic disease.
    Type: Grant
    Filed: April 14, 2017
    Date of Patent: May 29, 2018
    Assignees: The Scripps Research Institute, The California Institute for Biomedical Research
    Inventors: Luke Lairson, Michael Bollong, Peter G. Schultz, Arnab K. Chatterjee, Baiyuan Yang, Puneet Kumar, Kaveri Urkalan
  • SWITCHABLE NON-scFv CHIMERIC RECEPTORS, SWITCHES, AND USES THEREOF
    Publication number: 20180118808
    Abstract: Disclosed herein are switchable chimeric receptors, switchable chimeric receptor effector cells and chimeric receptor effector cell switches. The switchable chimeric receptor-ECs are generally T cells. The chimeric receptors have non-antibody extracellular domains that recognize a chimeric receptor binding partner on the chimeric receptor-EC switch or target cell. The chimeric receptor-ECs and switches may be used for the treatment of a disease or condition in a subject in need thereof.
    Type: Application
    Filed: March 28, 2016
    Publication date: May 3, 2018
    Applicant: The California Institute for Biomedical Research
    Inventors: Travis YOUNG, Chanhyuk KIM, Peter G. SCHULTZ
  • CHIMERIC ANTIGEN RECEPTOR T CELL SWITCHES AND USES THEREOF
    Publication number: 20180104354
    Abstract: Disclosed herein are switches for regulating the activity of a chimeric antigen receptor effector cells (CAR-ECs). The switches generally comprise a chimeric antigen receptor-interacting domain (CAR-ID) and a target interacting domain (TID). The switch may further comprise a linker. Further disclosed herein are methods of using the switches for the treatment of one or more conditions or diseases in a subject in need thereof.
    Type: Application
    Filed: July 7, 2017
    Publication date: April 19, 2018
    Inventors: Chanhyuk Kim, Travis Young, Yu Cao, Jennifer Ma, Minsoo Kim, Stephanie A. Pinkerton, Peter G. Schultz
  • OPTIMIZED CHIMERIC RECEPTOR T CELL SWITCHES AND USES THEREOF
    Publication number: 20180100026
    Abstract: Disclosed herein are switches for regulating the activity of a chimeric antigen receptor effector cells (CAR-ECs). The switches generally comprise a chimeric antigen receptor-interacting domain (CAR-ID) and a target interacting domain (TID). The switch may further comprise a linker. Further disclosed herein are methods of using the switches for the treatment of one or more conditions or diseases in a subject in need thereof.
    Type: Application
    Filed: April 15, 2016
    Publication date: April 12, 2018
    Inventors: Chanhyuk KIM, Travis YOUNG, Jennifer MA, Ji Young KIM, Xinxin WANG, Eduardo LABORDA, Peter G. SCHULTZ
  • SMALL MOLECULE INHIBITORS OF FIBROSIS
    Publication number: 20170362211
    Abstract: Described herein are compounds and compositions for the treatment of a fibrotic disease.
    Type: Application
    Filed: December 9, 2015
    Publication date: December 21, 2017
    Inventors: Luke LAIRSON, Arnab K. CHATTERJEE, Michael BOLLONG, Baiyuan YANG, Peter G. SCHULTZ
  • METHODS OF CONSTRUCTING AMINO TERMINAL IMMUNOGLOBULIN FUSION PROTEINS AND COMPOSITIONS THEREOF
    Publication number: 20170327577
    Abstract: Disclosed herein are immunoglobulin fusion proteins comprising a first immunoglobulin region attached to a therapeutic peptide at the amino terminus of the immunoglobulin region. The immunoglobulin fusion proteins may further comprise a second immunoglobulin region. The immunoglobulin fusion protein may further comprise one or more connecting peptides, linkers, proteolytic cleavage sites, internal linkers, or a combination thereof. The immunoglobulin fusion proteins may further comprise one or more additional therapeutic peptides. Also disclosed herein are compositions comprising the immunoglobulin fusion proteins and methods for using the immunoglobulin fusion proteins for the treatment or prevention of a disease or condition in a subject.
    Type: Application
    Filed: June 5, 2015
    Publication date: November 16, 2017
    Inventors: Feng WANG, Yan LIU, Ying WANG, Guangsen FU, Peter G. SCHULTZ
  • Unnatural reactive amino acid genetic code additions
    Patent number: 9797908
    Abstract: This invention provides compositions and methods for producing translational components that expand the number of genetically encoded amino acids in eukaryotic cells. The components include orthogonal tRNAs, orthogonal aminoacyl-tRNA synthetases, orthogonal pairs of tRNAs/synthetases and unnatural amino acids. Proteins and methods of producing proteins with unnatural amino acids in eukaryotic cells are also provided.
    Type: Grant
    Filed: July 22, 2014
    Date of Patent: October 24, 2017
    Assignee: The Scripps Research Institute
    Inventors: Alexander Deiters, T. Ashton Cropp, Jason W. Chin, J. Christopher Anderson, Peter G. Schultz
  • Site-specific incorporation of redox active amino acids into proteins
    Patent number: 9783798
    Abstract: Compositions and methods of producing components of protein biosynthetic machinery that include orthogonal tRNAs, orthogonal aminoacyl-tRNA synthetases, and orthogonal pairs of tRNAs/synthetases, which incorporate redox active amino acids into proteins are provided. Methods for identifying these orthogonal pairs are also provided along with methods of producing proteins with redox active amino acids using these orthogonal pairs.
    Type: Grant
    Filed: January 5, 2012
    Date of Patent: October 10, 2017
    Assignee: The Scripps Research Institute
    Inventors: Lital Alfonta, Peter G. Schultz, Zhiwen Zhang
  • PEPTIDIC CHIMERIC ANTIGEN RECEPTOR T CELL SWITCHES AND USES THEREOF
    Publication number: 20170246270
    Abstract: Disclosed herein are chimeric antigen receptor effector cells (CAR-ECs) and CAR-EC switches. The switchable CAR-ECs are generally T cells. The one or more chimeric antigen receptors may recognize a peptidic antigen on the CAR-EC switch. The CAR-ECs and switches may be used for the treatment of a condition in a subject in need thereof.
    Type: Application
    Filed: March 2, 2017
    Publication date: August 31, 2017
    Inventors: Travis YOUNG, Chanhyuk KIM, Peter G. SCHULTZ
  • COMPOUNDS THAT EXPAND HEMATOPOIETIC STEM CELLS
    Publication number: 20170239296
    Abstract: The present invention relates to compounds and compositions for expanding the number of CD34+ cells for transplantation. The invention further relates to a cell population comprising expanded hematopoietic stem cells (HSCs) and its use in autologous or allogeneic transplantation for the treatment of patients with inherited immunodeficient and autoimmune diseases and diverse hematopoietic disorders to reconstitute the hematopoietic cell lineages and immune system defense.
    Type: Application
    Filed: January 18, 2017
    Publication date: August 24, 2017
    Inventors: Anthony E. Boitano, Michael Cooke, Shifeng Pan, Peter G. Schultz, John Tellew, Yongqin Wan, Xing Wang
  • In vivo unnatural amino acid expression in the methylotrophic yeast
    Patent number: 9732349
    Abstract: The invention provides orthogonal translation systems for the production of polypeptides comprising unnatural amino acids in methylotrophic yeast such as Pichia pastoris. Methods for producing polypeptides comprising unnatural amino acids in methylotrophic yeast such as Pichia pastoris are also provided.
    Type: Grant
    Filed: January 27, 2014
    Date of Patent: August 15, 2017
    Assignee: The Scripps Research Institute
    Inventors: Travis Young, Peter G. Schultz
  • SMALL MOLECULE INHIBITORS OF FIBROSIS
    Publication number: 20170217943
    Abstract: Described herein are compounds and compositions for the treatment of a fibrotic disease.
    Type: Application
    Filed: April 14, 2017
    Publication date: August 3, 2017
    Inventors: Luke LAIRSON, Michael BOLLONG, Peter G. SCHULTZ, Arnab K. CHATTERJEE, Baiyuan YANG, Puneet KUMAR, Kaveri URKALAN